These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 26390969)
41. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells. Hsu FN; Chen MC; Lin KC; Peng YT; Li PC; Lin E; Chiang MC; Hsieh JT; Lin H Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E975-86. PubMed ID: 23941877 [TBL] [Abstract][Full Text] [Related]
42. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells. Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954 [TBL] [Abstract][Full Text] [Related]
44. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052 [TBL] [Abstract][Full Text] [Related]
45. The RAS and YAP1 dance, who is leading? Corbo V; Ponz-Sarvise M; Tuveson DA EMBO J; 2014 Nov; 33(21):2437-8. PubMed ID: 25257311 [TBL] [Abstract][Full Text] [Related]
46. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal. Hofer MD Fundam Clin Pharmacol; 2018 Oct; 32(5):547. PubMed ID: 30209857 [No Abstract] [Full Text] [Related]
47. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511 [TBL] [Abstract][Full Text] [Related]
48. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370 [TBL] [Abstract][Full Text] [Related]
49. Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells. Zhang L; Zhao Z; Xu S; Tandon M; LaValle CR; Deng F; Wang QJ Oncotarget; 2017 Feb; 8(8):12800-12811. PubMed ID: 28077787 [TBL] [Abstract][Full Text] [Related]
50. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740 [TBL] [Abstract][Full Text] [Related]
51. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. Yu M; Chen Y; Li X; Yang R; Zhang L; Huangfu L; Zheng N; Zhao X; Lv L; Hong Y; Liang H; Shan H Cell Death Dis; 2018 May; 9(5):464. PubMed ID: 29700328 [TBL] [Abstract][Full Text] [Related]
52. Are androgen receptor variants a substitute for the full-length receptor? Lu J; Van der Steen T; Tindall DJ Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893 [TBL] [Abstract][Full Text] [Related]
53. Intracrine androgen biosynthesis in renal cell carcinoma. Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524 [TBL] [Abstract][Full Text] [Related]
54. Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis. Assinder SJ; Beniamen D; Lovicu FJ Biomed Res Int; 2015; 2015():827462. PubMed ID: 26075267 [TBL] [Abstract][Full Text] [Related]
55. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. Edwards J; Bartlett JM BJU Int; 2005 Jun; 95(9):1320-6. PubMed ID: 15892825 [No Abstract] [Full Text] [Related]
56. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo. Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600 [TBL] [Abstract][Full Text] [Related]
57. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor. Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496 [TBL] [Abstract][Full Text] [Related]
58. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma. Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598 [TBL] [Abstract][Full Text] [Related]
59. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome. Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812 [TBL] [Abstract][Full Text] [Related]
60. AR Pathway Is Involved in the Regulation of CX43 in Prostate Cancer. Chen R; Luan Y; Liu Z; Song W; Wu L; Li M; Yang J; Liu X; Wang T; Liu J; Ye Z Biomed Res Int; 2015; 2015():514234. PubMed ID: 26491675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]